Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCXH-105 Safety and Immunogenicity in Healthy Adults 50-69
NCT05871541Phase 1Completed
- Sponsor
- Immorna
- Start
- May 2023
- Primary completion
- Mar 2024
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JCXH-105 in herpes zoster (HZ) (2 arms), sponsored by Immorna. Primary endpoints: Serious Adverse Event Frequency, Injection site reaction frequency and 4 more. Started May 2023; status: completed.
02
Drugs
JCXH-105
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT05871541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05871541.